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Background: Chronic obstructive pulmonary disease (COPD) is accompanied by an increased
cardiovascular risk which is aggravated by the incidence of acute exacerbations (AE). Endothe-
lial function, as well as the soluble receptor for advanced glycation end-products (sRAGE),
both markers of cardiovascular risk, has been shown to be decreased in stable COPD.
Objectives: We aimed to investigate a possible link between sRAGE and endothelial function in
AE of COPD. We hypothesize that circulating levels of sRAGE and endothelial function are
impaired during AE and improve after clinical recovery, respectively.
Methods: We enrolled patients admitted to hospital due to an AE of COPD without overt car-
diovascular comorbidities. Study related procedures comprised spirometry, measurement of
plasma sRAGE levels and the quantification of endothelial function by means of the flow-
mediated dilation technique (FMD). All measurements were scheduled during hospitalization
and after confirmed clinical stability.
Results: We recruited 29 patients (27% female) with moderate to severe COPD. Median sRAGE
concentration was 525 pg/mL (371e770, 1ste3rd quartile) and mean FMD 6.7  3.6% at AE.
There was a significant increase of sRAGE levels to 876 pg/mL (633e1371, 1ste3rd quartile,
p < 0.001) and a simultaneous improvement in FMD (10.0  3.4%, p < 0.001) after clinical re-
covery. There was a significant positive association between sRAGE and FMD (regressionrbation; AGE, advanced glycation end-products; COPD, chronic obstructive pulmonary disease; CRP,
iratory volume in one second; FMD, flow-mediated dilation; FVC, forced vital capacity; mRAGE,
tion end-products; RAGE, receptor of advanced glycation end-products; sRAGE, soluble receptor of
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892 M.H. Urban et al.coefficient Z 2.43; p Z 0.01) in our study sample.
Conclusion: Our results indicate a substantial decrease in sRAGE levels and endothelial func-
tion during AE, with evidence of improvements after clinical recovery. sRAGE may contribute
to cardiovascular risk in COPD.
ª 2014 Elsevier Ltd. All rights reserved.Introduction
Acute exacerbations (AE) of chronic obstructive pulmonary
disease (COPD) are characterized by an excess risk of
mortality during and immediately after hospitalization [1].
The individual prognosis furthermore worsens with
increasing exacerbation rate. Cardiovascular events are
major determinants of COPD related mortality in stable
phase of disease [2e4] and were shown to accumulate with
the occurrence of AE [5]. Recent observations identified
endothelial dysfunction, a surrogate of subclinical athero-
sclerosis, in patients with COPD [6,7]. Moreover, AEs are
accompanied by a temporary worsening of endothelial
dysfunction [8]. However, the distinct mechanisms for
these circumstances remain unclear.
The soluble receptor for advanced glycation end-products
(sRAGE), a novel biomarker in inflammatory disease entities
was recently shown to be deteriorated in patients with COPD
and to further decrease during AEs [9]. sRAGE is considered an
important surrogate for coronary artery disease [10]. The
current understanding delineates anti-atherogenic effects of
sRAGE via decoy of advanced glycation end-products which
were shown to trigger inflammatory actions associated with
atherosclerosis. We have previously shown a relationship be-
tween systemic inflammation and endothelial dysfunction in
patients with COPD. Thus, we aimed to investigate the link
between sRAGE and endothelial dysfunction in patients with
COPD free from any cardiovascular disease. We hypothesize
that sRAGE levels and endothelial function are both
decreased during AE and increase after clinical recovery. This
study aims to provide novel insight into the complex patho-
genesis of COPD related cardiovascular disease and to char-
acterize the consequences of AEs in atherosclerosis prone
subjects at early stages of disease.Methods
Study population
The study recruitment was performed from January 2006 to
March 2009. We enrolled patients admitted to our hospital
because of an AE of COPD. Inclusion criteria comprised
diagnosis of COPD [11], an AE according to recommended
international criteria [12], an age of over 40 years and a
smoking history of at least 10 pack years. Exclusion criteria
included overt cardiovascular disorders (i.e. arterial hy-
pertension, coronary artery disease, myocardial infarction,
congestive heart failure). Moreover, subjects with pneu-
monia, interstitial lung disease, acute or chronic renal
failure, active malignancy, autoimmune disease, diabetes
or hypercholesterolemia were excluded.Sample size calculation
In contrast to sRAGE the dynamics of FMD are well
described during and after AE of COPD. Therefore, we used
FMD for sample size calculation. Based on a measured FMD
of 11  2% in stable COPD [6], we estimated a 50% reduction
in FMD during AE (alpha error probabilityZ 0.01; Beta error
probability Z 0.95). The required sample size for a paired
t-test is n Z 8. According to recommendations on the size
of studies using FMD [13] we planned to include 28 patients.
This accounts for a maximum estimated proportion of pa-
tient lost-to-follow of 70%.Study procedures
Patients were examined within 48 h after hospitalization
and after clinical recovery. Demographics and a detailed
medical history were recorded once at the time of hospi-
talization. Patients underwent a standard physical exami-
nation and a 6-min walking test following the current
guidelines [14].Measurements
Laboratory parameters
After a 12-h fasting period blood samples were taken from
all patients and analyzed for metabolic (i.e. fasting blood
glucose, HbA1c, cholesterol, triglycerides) and inflamma-
tory biomarkers (i.e. leukocyte- and neutrophil-counts, C-
reactive protein). For assessment of sRAGE blood samples
were centrifuged for 10 min at 2500 rpm, stored in a lab
freezer at 84C and analyzed via QUANTIKINE ELISA kits
(R&D Systems, Minneapolis).
Endothelial dysfunction
For quantification of endothelial dysfunction we conducted
the Flow-Mediated Dilation (FMD) technique as described
previously [13]. In brief, the dilatory capacity of the
brachial artery induced by reactive hyperemia was assessed
via ultrasonographic depiction of the vessels luminal
diameter. Percentage changes of the baseline diameter are
due to endogenous nitric oxide release following endothe-
lial shear stress and represent a validated estimation of
subclinical atherosclerosis.
Pulmonary function testing
Lung function was assessed by means of post-
bronchodilator spirometry (V6200; Sensormedics) accord-
ing to the current guidelines [15].
Table 1 Baseline characteristics of study subjects.
Parameters n Z 29
Age, years 64  7.6
Gender, male 27%
Height, centimeter 164  32
Weight, kilogram 72  19
BMI 25  5.8
Smoking history, pack years 69  46
Exacerbations per year 1.8  1.2
6-min walk test, meter 342  122
Modified medical research council scale 2.4  1.0
Bode-index 4.9  2.1
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Samples for blood gas analysis (AVL Compact 3 Analyzer;
Roche, Austria) were taken from the radial artery with
patient’s breathing room air.
Data analysis
Data descriptions
Nominal data were described as cell frequencies of each
level and percentages. Ordinal data were described as cell
frequencies of each level and percentages or as median and
1ste3rd quartiles. Scale data with a normal distribution
were described as arithmetic mean and standard deviation.
Interval data with a non-normal distribution were described
as median and 1ste3rd quartiles.
Test-statistical methods
Data distribution was visually assessed via histograms and
PeP-plots (ProbabilityeProbability-Plot), exact calcula-
tions were performed by the ShapiroeWilks test. Normally
distributed scale variables were compared intra-
individually using a paired t-test. When possible non-
normally distributed variables were logarithm transformed
and the geometric mean was reported. Ordinal variables
were compared using Wilcoxon’s matched-pairs test. In
order to account for intra-individual interrelation, we used
a generalized estimating equation to study the association
between FMD and sRAGE. We were assuming an exchange-
able correlation matrix for repeated observations within
one patient [16]. A two-sided p-value <0.05 was considered
statistically significant. Statistical analyses were performed
using SPSS version 15.0 software (SPSS Inc., Chicago,
Illinois).
Ethics
Following comprehensive instruction explaining the nature
and purpose of the study patients had to give written
consent prior to participation in the study. The protocol
was approved by the ethics committee of the Vienna City
Council (EC-number: EK-05-151-1205). The study was con-
ducted in full accordance with the Declaration of Helsinki.
The reporting of this observational study is in accordance
with the “Strengthening the Reporting of Observational
Studies in Epidemiology” (STROBE) Statement [17]. Some of
the results of these studies have been previously reported
in the form of an abstract.
Results
Subject characteristics
A total of 296 patients were screened of which 257 were
ineligible. Reasons for ineligibility comprised arterial hy-
pertension (n Z 83), diabetes (n Z 48), congestive heart
failure (n Z 46), coronary artery disease (n Z 41), chronic
renal failure (n Z 21), active malignancy (n Z 12) and
interstitial lung disease (n Z 6). 8 subjects refused to
participate and 2 patients were lost to follow-up. We finally
included 29 patients with an AE of COPD in this study.Subject characteristics are outlined in Table 1. The fre-
quency of GOLD stage II, III and IV was 3 (10.3%), 14 (48.3%)
and 12 (41.4%), the GOLD risk class A, B, C and D was 2
(6.9%), 2 (6.9%), 5 (17.2%) and 20 (69%) respectively. The
median interval from the first (AE) to the second visit (re-
covery) was 8.0 weeks (7e13, 1ste3rd quartile).
Spirometric and laboratory parameters during and after
AE of COPD
The mean FEV1 was 37  12% predicted and the FEV1/FVC
ratio during AE was 42  11%.
Parameters of lung function, blood gas analysis, glucose-
and lipid-metabolism as well as inflammatory markers at AE
and recovery are listed in Table 2. The entire spectrum of
inflammatory markers declined over the observation
period: The changes between AE and recovery in absolute
counts of leukocytes (9.7  3.4 vs. 8.2  2.9, pZ 0.018) as
well as neutrophils (7.5  3.2 vs. 5.5  2.8, p Z 0.004)
achieved statistical significance. The median amount of
CRP during AE was 7.0 (2.0e28, 1ste3rd quartile) and
decreased to 4.0 (2.0e7.0, 1ste3rd quartile) until clinical
stability (p Z 0.025).
sRAGE during and after AE of COPD
The median level of sRAGE during AE was 525 (371e770,
1ste3rd quartile) pg/mL. Having reached clinical stability
our patients revealed a significant improvement of median
sRAGE to 876 (633e1371, 1ste3rd quartile) pg/mL
(p < 0.001) as depicted in Fig. 1. In comparison, Gopal
et al. [18] amounted an average level of sRAGE for healthy
control subjects to 1477.66  668.68 pg/mL. In line with
that, sample values from the serum of healthy subjects
provided by the manufacturer of the ELISA kit were at an
average level of 1794  755 pg/mL.
Endothelial function during and after AE of COPD
FMD values during AE and recovery are depicted in Fig. 2.
During acute exacerbation FMD was substantially impaired
(6.7  3.6, %) and improved after recovery (10  3.4, %)
(p < 0.001), but not reaching values of normal subjects.
Association between sRAGE and endothelial dysfunction
We observed a significant positive association between
sRAGE and FMD (coefficient Z 2.43; p Z 0.01) (Fig. 3). We
observed an inverse correlation between changes of sRAGE
and neutrophil counts (regression coefficient Z 0.389;
Table 2 Subject characteristics during and after acute exacerbations of COPD.
Variables Acute exacerbation Recovery p-Value
Lung function
VC, %pred 74  22 76  13 0.495
FEV1, %pred 37  12 36  13 0.565
FEV1/FVC, % 42  11 39  12 0.132
Arterial pO2, mmHg 68  11 67  14 0.700
Arterial PCO2, mmHg 41  5.8 40  7.1 0.096
Metabolic
Glucose, mmol/L 5.6 (5.1e6.0) 5.3 (4.3e5.9) 0.375
HbA1c, mmol/mol 37 (34e39) 36 (33e39) 0.718
Total cholesterol, mmol/L 4.7  1.0 4.9  1.1 0.085
Triglycerides, mmol/L 1.2  0.45 1.1  0.38 0.545
Inflammation
Leukocyte count, 103/UL 9.7  3.4 8.2  2.9 0.018
Neutrophil count, 103/UL 7.5  3.2 5.5  2.8 0.004
CRP, geometric mean, (CI) 7.6 (4.2e14) 4.0 (2.9e5.5) 0.025
Cardiovascular
FMD, % 6.7  3.6 10  3.4 <0.001
NMD, % 15  5.0 18  6.1 0.006
sRAGE, geometric mean (CI) 534 (425e672) 923 (760e1121) <0.001
894 M.H. Urban et al.p Z 0.045) from AE to recovery. No association was ob-
tained for other inflammatory markers of parameters of
spirometry (data not shown).Discussion
The current study provides evidence of impaired levels of
circulating sRAGE as well as aggravated endothelial
dysfunction during AE of COPD. Both endpoints showed a
significant improvement from AE to clinical recovery.
Notably, we observed a strong positive association between
sRAGE and FMD in our sample. This study is the first to
suggest AE as a potential determinant of endothelial
dysfunction and cardiovascular risk via deteriorated circu-
lating sRAGE levels in patients with COPD.Figure 1 Plasma sRAGE levels in patients with COPD (nZ 29)
during AE and after clinical recovery (P < 0.001, for log
transformed sRAGE).Cardiovascular events are among the most relevant
causes of death in COPD [19]. Impaired lung function is a
strong determinant of cardiac events, even stronger than
traditional cardiovascular risk factors [20,21]. The distinct
mechanisms however remain unclear. Recent studies un-
derline the role of AE as a trigger of cardiac events [22,23].
Established cardiovascular biomarkers like the N-terminal
pro natriuretic peptide or troponin-T are associated with
increased mortality during and after an AE of COPD.
The receptor for advanced glycation end-products
(RAGE) has recently been suggested to participate in the
development of atherosclerosis [10,24]. This trans-
membrane receptor is capable of binding to several ligands
like advanced glycation end-products (AGE) [25]. AGEs are
adducts generated by oxidation and glycation which accu-
mulate in various inflammatory diseases. RAGE-ligandFigure 2 Flow-mediated dilation in patients with COPD
(n Z 29) during AE and after clinical recovery (P < 0.001).
Figure 3 Association between sRAGE and flow-mediated
dilation (n Z 29) during AE and after recovery (Regression
coefficient Z 2.43; p Z 0.01). x aches: sRAGE logarithm
transformed.
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disorders like rheumatoid arthritis, diabetes and most
notably atherosclerosis [25e27]. Apart from the membrane
bound RAGE (mRAGE), sRAGE characterizes the soluble
isoform of the receptor that lacks the transmembrane
signaling domain. sRAGE fulfills a decoy function preventing
the interaction of AGE with mRAGE and consequently holds
anti-atherogenic effects comprising inhibition of pro-
coagulant activity, oxidative stress and inflammation [28].
Thus, sRAGE seems to emerge as a valid biomarker of
atherosclerotic disorders [29].
In line with our findings, a recent publication found a
strong association between sRAGE and FMD in 180 patients
with coronary artery disease [30]. In a 48 month follow-up
the authors revealed that higher sRAGE levels are associ-
ated with a significantly longer event-free survival.
Eickhoff et al. [6] were the first to demonstrate the
presence of endothelial dysfunction, a validated marker of
cardiovascular risk, in patients with stable COPD compared
to matched controls. The authors characterized airflow
limitation as well as systemic inflammation as major de-
terminants of endothelial dysfunction in stable COPD.
Could sRAGE be an explanation for vascular disease in
COPD patients? Our cohort showed significantly lower levels
of plasma sRAGE and FMD during AE compared to mea-
surement after convalescence. A paper published by Ozben
[8] dealt with the temporary alteration of FMD during AE.
The authors observed a significantly impaired FMD during
AE compared to subsequent recovery as well as healthy
controls. As in our study they did not discover a significant
association between airflow limitation and FMD. However,
the Ozben study lacks the assessment of important labo-
ratory parameters like inflammatory markers to account for
potential determinants of the observed FMD impairment.
Consequently, our findings of a temporarily impaired
vascular integrity via impaired sRAGE levels during AEs are
a novelty to the field.
A study by Smith et al. [9] previously investigated the
role of sRAGE as a serological biomarker in COPD. Their
data documented attenuated sRAGE levels in patients withstable COPD compared to controls. Our present study in-
dicates a significant reduction of circulating sRAGE levels
via longitudinal assessment during and after AEs of COPD.
Consistently, Smith and colleagues observed a decreased
amount of plasma sRAGE in a subgroup of their patients
developing an AE. They concluded that aggravated inflam-
mation might be responsible for the temporary suppression
of circulating sRAGE. In our cohort we found no statistically
significant correlation between the improvement of sRAGE
and CRP levels. However, changes in sRAGE showed a sig-
nificant correlation to absolute neutrophil count
(rZ 0.389, pZ 0.045) underlining the impact of systemic
inflammation on sRAGE. This finding is strengthened by the
observation of Sukkar et al. [31] that patients with
neutrophilic asthma or COPD had significantly lower sRAGE
levels then patients without neutrophilia. As a potential
underlying mechanism for sRAGE deficiency Sukkar et al.
suggest proteolytic enzymes derived from neutrophils on
the one hand. On the other hand, a reduced antagonism of
RAGE signaling via ligands like serum amyloid A (SAA), high-
mobility group box-1 (HMGB1) or the advanced glycation
endproducts could result in augmented oxidative stress and
inflammation. Similar findings were discussed in patients
with cystic fibrosis [32]. The question whether sRAGE defi-
ciency triggers neutrophilic inflammation, or inflammatory
enzymes deteriorate levels of sRAGE will probably remain a
matter of debate and cannot be clarified through our
findings.
We did not find a significant association between
markers of airflow limitation and levels of sRAGE. Smith
et al. identified sRAGE as the strongest predictor of FEV1.
They constitute sRAGE as an even more powerful predictor
of COPD than CRP. In contrast, a recent study by Miniati
[33], found conflicting results concerning sRAGE levels in
COPD patients stratified by FEV1. Subjects with an FEV1
above 50 percent predicted revealed a median sRAGE of
660 pg/mL, those with an FEV1 below 50 percent predicted
had 763 pg/mL, whereas the group with the highest airflow
limitation again had the lowest amount of sRAGE (435 pg/
mL). In contrast, this study assessed a significant associa-
tion between sRAGE and emphysema severity as well as
lung diffusing capacity. The authors assigned the observed
reduction of sRAGE in COPD to an extensive disruption of
lung parenchyma.
Are there any potential clinical applications for sRAGE?
Quantification of circulating sRAGE might be diagnostically
utilized for early characterization of subjects at increased
cardiovascular risk. Therapeutic implications are suggested
by a study published in 1998 [27] which evaluated the ef-
fects of sRAGE administration in diabetic mouse models and
observed a significant suppression of early atherosclerosis.
In fact substitution of sRAGE might characterize a promising
approach for future studies aiming to prevent atheroscle-
rosis in sRAGE deficient populations like COPD.
Consequently, the clinical relevance of sRAGE in COPD
might include early characterization of subjects at
increased cardiovascular risk with consecutive therapeutic
implications. Prospective studies are needed to test the
benefit of risk stratification via plasma sRAGE levels. The
effects of preventive as well as therapeutic strategies
aiming at the reduction of cardiovascular risk in sRAGE
selected subgroups might be tested. Finally, the
896 M.H. Urban et al.substitution of sRAGE might have beneficial effects on
vascular health in COPD patients prone to frequent
exacerbations.
Strengths and limitations of the study
We were the first to investigate an association between
sRAGE and FMD in patients with COPD. A further strength of
this study is the prospective cohort design. From AE to
clinical recovery only 2 subjects were excluded due to loss
to follow up. The stringent exclusion criteria resulted in a
properly selected study sample without overt cardiovascu-
lar diseases. Consequently, our findings depict COPD
related atherogenesis at a subclinical and potentially
reversible phase prior to the manifestation of end-organ
damage.
Study limitations include the limited sample size which
avoided the conduction of multivariate analysis. Associa-
tions between sRAGE and markers of airflow limitation or
CRP as described in the previous literature might have
possibly been overlooked due to a lack of power in the
respective correlations. Moreover, we can only hypothesize
about the baseline parameters prior to AEs as the assess-
ment started at the time of hospitalization. However, the
reassessment of our cohort after clinical recovery serves as
an intra-individual control. Furthermore, we did not
include a control group of healthy subjects. Yet, normal
values for sRAGE do already exist in previous literature and
were also provided by the manufacturers of the sRAGE-
ELIAS kits.
Conclusion
Our study is the first to suggest decreased sRAGE as a po-
tential mediator for endothelial dysfunction in AE of COPD.
Moreover, novel insights are given into the role of AE as a
determinant of endothelial dysfunction and therefore
morbidity and mortality. Our data favor sRAGE as a poten-
tial link between AE and the excess occurrence of cardio-
vascular events in COPD.
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